Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 543 Neoplasms 449 Carcinoma, Non-Small-Cell Lung 410 Prostatic Neoplasms 334 Colorectal Neoplasms 315 Lung Neoplasms 261 Multiple Myeloma 229 Neoplasm Metastasis 190 Pancreatic Neoplasms 186 Leukemia, Myeloid, Acute 183 Ovarian Neoplasms 178 Melanoma 147 Squamous Cell Carcinoma of Head and Neck 140 Carcinoma, Hepatocellular 116 Recurrence 115 Head and Neck Neoplasms 114 Carcinoma, Renal Cell 112 Lymphoma 111 Stomach Neoplasms 110 Endometrial Neoplasms 110 Precursor Cell Lymphoblastic Leukemia-Lymphoma 109 Glioblastoma 108 Brain Neoplasms 106 Lymphoma, Non-Hodgkin 105 Uterine Cervical Neoplasms 100 Triple Negative Breast Neoplasms 97 Urinary Bladder Neoplasms 95 Hematologic Neoplasms 91 Leukemia, Lymphocytic, Chronic, B-Cell 88 Lymphoma, Large B-Cell, Diffuse 84

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × 30 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡